Argenx stock price target reiterated at $761 on positive trial data

TD Cowen reiterated its Buy rating and $761 price target on argenx SE (ARGX) after positive Phase 2/3 trial results for VYVGART in myositis and Sjogren's disease, meeting primary endpoints and indicating multibillion-dollar upside potential. First-quarter earnings also exceeded expectations with Vyvgart net sales surpassing estimates at $790 million, although analysts have mixed views on the stock, with some maintaining or upgrading ratings while Deutsche Bank reduced its price target due to mixed performance.

Analysis

Argenx SE (ARGX) has received a significant endorsement from TD Cowen, which reiterated its Buy rating and $761.00 price target following highly promising clinical trial results for its VYVGART therapy. The Phase 2/3 ALKIVIA trial for VYVGART in myositis met its primary endpoint with a statistically significant mean Total Improvement Score at week 24, alongside key secondary endpoints. Concurrently, the Phase 2 RHO trial for VYVGART in Sjogren’s disease also achieved its primary endpoint, leading TD Cowen to label these outcomes a "best case scenario" that validates the therapy's biological mechanism and indicates "multibillion $ upside" potential. This clinical progress is complemented by argenx's strong financial position, highlighted by a "GREAT" overall score on InvestingPro’s health assessment and first-quarter 2025 earnings that exceeded expectations. Vyvgart's net sales of $790 million surpassed consensus ($784 million) and TD Cowen's ($775 million) projections, despite increased gross-to-net discounts due to the Medicare Part D redesign. Analyst sentiment is largely positive, with H.C. Wainwright maintaining a Buy ($720 PT), Baird upgrading to Outperform ($680 PT), and JMP Securities maintaining Outperform ($699 PT), all citing factors like drug development strategy, sales growth, and anticipated demand for new Vyvgart formulations. However, Deutsche Bank presents a more cautious stance, maintaining a Hold rating and reducing its price target to EUR525, citing mixed first-quarter performance aspects and concerns about sustaining commercial momentum for the $35.3 billion market cap company. Argenx is set to present further Phase 2 data at the EULAR conference, which will be a key event for ongoing assessment.

Key Decisions for Investors

• Investors should consider the successful Phase 2/3 trial results for VYVGART in myositis and Sjogren's disease as significant de-risking events that substantially enhance the therapy's growth prospects and potential for multi-billion dollar revenue expansion beyond current indications.
• Closely monitor argenx's presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) conference, as detailed Phase 2 data for VYVGART in these new conditions could serve as important near-term catalysts for the stock.
• Evaluate the strong Q1 2025 earnings and Vyvgart net sales of $790 million, which surpassed expectations despite Medicare Part D headwinds, against the backdrop of varied analyst price targets and Deutsche Bank's more cautious Hold rating concerning the sustainability of commercial momentum.